1 |
Jia L , Du Y , Chu L , Zhang Z , Li F , Lyu D , Li Y , Li Y , Zhu M , Jiao H , Song Y , Shi Y , Zhang H , Gong M , Wei C , Tang Y , Fang B , Guo D , Wang F , Zhou A , Chu C , Zuo X , Yu Y , Yuan Q , Wang W , Li F , Shi S , Yang H , Zhou C , Liao Z , Lv Y , Li Y , Kan M , Zhao H , Wang S , Yang S , Li H , Liu Z , Wang Q , Qin W , Jia J , COAST Group . Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health, 2020, 5: e661- e671.
doi: 10.1016/S2468-2667(20)30185-7
|
2 |
Ren R , Qi J , Lin S , Liu X , Yin P , Wang Z , Tang R , Wang J , Huang Q , Li J , Xie X , Hu Y , Cui S , Zhu Y , Yu X , Wang P , Zhu Y , Wang Y , Huang Y , Hu Y , Wang Y , Li C , Zhou M , Wang G . The China Alzheimer report 2022. Gen Psychiatr, 2022, 35: e100751.
doi: 10.1136/gpsych-2022-100751
|
3 |
Ren RJ , Yin P , Wang ZH , Qi JL , Tang R , Wang JT , Huang Q , Li JP , Xie XY , Hu YB , Cui SS , Yu XP , Zhu Y , Liu XY , Zhu YK , Lin SH , Wang YR , Huang YY , Hu YS , Wang XF , Wang HL , Chu JS , Wang Y , Li CB , Zhou MG , Wang G . Chinese Alzheimer's disease report 2021. Zhen Duan Xue Li Lun Yu Shi Jian, 2021, 20: 317- 337.
URL
|
|
任汝静, 殷鹏, 王志会, 齐金蕾, 汤然, 王金涛, 黄强, 李建平, 谢心怡, 胡勇博, 崔诗爽, 余小萍, 朱圆, 刘馨雅, 朱怡康, 林绍慧, 王怡然, 黄延焱, 胡以松, 王学锋, 王鸿利, 褚敬申, 王颖, 李春波, 周脉耕, 王刚. 中国阿尔茨海默病报告2021. 诊断学理论与实践, 2021, 20: 317- 337.
URL
|
4 |
Zhu Y , Yu XP , Wang G . Suggestions for home care of people with dementia based on community support. A Er Ci Hai Mo Bing Ji Xiang Guan Bing, 2023, 6: 77- 84.
URL
|
|
朱圆, 余小萍, 王刚. 老年痴呆患者基于社区支持的居家照护的专家建议. 阿尔茨海默病及相关病, 2023, 6: 77- 84.
URL
|
5 |
Li JP , Ren RJ , Wang G . Progress in clinical diagnosis and treatment of Alzheimer's disease. Zhen Duan Xue Li Lun Yu Shi Jian, 2022, 21: 18- 21.
URL
|
|
李建平, 任汝静, 王刚. 阿尔茨海默病的临床诊治进展. 诊断学理论与实践, 2022, 21: 18- 21.
URL
|
6 |
Imbimbo BP , Ippati S , Watling M , Imbimbo C . Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: insights from clinical trials with secretase inhibitors and monoclonal antibodies. Pharmacol Res, 2023, 187: 106631.
doi: 10.1016/j.phrs.2022.106631
|
7 |
Xiao JW , Ren RJ , Wang G . Anti-amyloid-β monoclonal antibodies for Alzheimer's disease: clinical practice and progress. A Er Ci Hai Mo Bing Ji Xiang Guan Bing, 2023, 6: 7- 11.
URL
|
|
肖金雯, 任汝静, 王刚. 论Aβ单抗治疗阿尔茨海默病的临床实践和进展. 阿尔茨海默病及相关病, 2023, 6: 7- 11.
URL
|
8 |
Budd Haeberlein S , Aisen PS , Barkhof F , Chalkias S , Chen T , Cohen S , Dent G , Hansson O , Harrison K , von Hehn C , Iwatsubo T , Mallinckrodt C , Mummery CJ , Muralidharan KK , Nestorov I , Nisenbaum L , Rajagovindan R , Skordos L , Tian Y , van Dyck CH , Vellas B , Wu S , Zhu Y , Sandrock A . Two randomized phase 3 studies of Aducanumab in early Alzheimer's disease. J Prev Alzheimers Dis, 2022, 9: 197- 210.
|
9 |
van Dyck CH , Swanson CJ , Aisen P , Bateman RJ , Chen C , Gee M , Kanekiyo M , Li D , Reyderman L , Cohen S , Froelich L , Katayama S , Sabbagh M , Vellas B , Watson D , Dhadda S , Irizarry M , Kramer LD , Iwatsubo T . Lecanemab in early Alzheimer's disease. N Engl J Med, 2023, 388: 9- 21.
doi: 10.1056/NEJMoa2212948
|
10 |
|
11 |
Cummings J , Aisen P , Apostolova LG , Atri A , Salloway S , Weiner M . Aducanumab: appropriate use recommendations. J Prev Alzheimers Dis, 2021, 8: 398- 410.
|
12 |
|
13 |
|
14 |
Cummings J , Rabinovici GD , Atri A , Aisen P , Apostolova LG , Hendrix S , Sabbagh M , Selkoe D , Weiner M , Salloway S . Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis, 2022, 9: 221- 230.
|
15 |
Cogswell PM , Barakos JA , Barkhof F , Benzinger TS , Jack CR Jr , Poussaint TY , Raji CA , Ramanan VK , Whitlow CT . Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice. AJNR Am J Neuroradiol, 2022, 43: E19- E35.
doi: 10.3174/ajnr.A7586
|
16 |
Reish NJ , Jamshidi P , Stamm B , Flanagan ME , Sugg E , Tang M , Donohue KL , McCord M , Krumpelman C , Mesulam MM , Castellani R , Chou SH . Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke. N Engl J Med, 2023, 388: 478- 479.
doi: 10.1056/NEJMc2215148
|